Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $18.19 Analyst target: $41.00 Upside: 125.40%
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies in the United States. The company is headquartered in Hayward, California.
See the full interactive analysis & chart →Informational only — not investment advice.